Chengdu Origen Biotechnology Co., Ltd.
Clinical trials sponsored by Chengdu Origen Biotechnology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a single gene shot replace monthly eye injections for wet AMD? Results expected Sep 2026 (estimated)
- One shot gene therapy could end monthly eye injections for wet AMD Results expected Jan 2027 (estimated)
-
One shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged…
Phase 1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a single gene shot replace monthly eye injections for wet AMD?
Disease control OngoingThis early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…
Phase 1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC